Friday 6 November 2026 Export ONC’s income statement to Excel — free account

BeOne Medicines Ltd. - Sponsored ADR

BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024.

Revenue: +33.8%
EPS: +143.7%
Free cash flow: +33.6%
Total debt: +491.3%

Quarter to September 2026, against a year earlier

407.13 19.88 +5.13%

Follow ONC

Alert me

Market cap: $40.4B
P/E: 65.9×
Fwd P/E: 48.8×
Dividend yield: —
F-score: 7/9
Altman Z: 5.25
Beneish M: −2.73
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

BeOne Medicines Ltd. - Sponsored ADR (ONC) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, BeOne Medicines Ltd. - Sponsored ADR (ONC) trades at a price to free cash flow of 30.4×. Over the past ten years it has ranged from 0.0× (June 2025) to 169× (September 2025); the current reading is higher than 91% of that period. That is above the Biotechnology industry median of 24.8× and above the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/ONC/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="BeOne Medicines Ltd. - Sponsored ADR price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/ONC/metrics/price-to-free-cash-flow">BeOne Medicines Ltd. - Sponsored ADR (ONC) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	35.9×	—
FY2024	0.0×	—
FY2023	0.0×	—
FY2022	0.0×	—
FY2021	0.0×	—
FY2020	0.0×	—
FY2019	0.0×	—
FY2018	0.0×	—
FY2017	0.0×	—
FY2016	0.0×	—

Period	Price to free cash flow	Change
Sep 2026	28.6×	17.72%
Jun 2026	24.3×	(19.38%)
Mar 2026	30.1×	(16.26%)
Dec 2025	35.9×	(49.78%)
40 more quarters	Free account

Against its own ten years

Low 0.0× High 169×

Ten-year median 0.0×

Current reading's percentile 91

Company	Price to free cash flow
ROIV Roivant Sciences Ltd. compare	n/m
GMAB Genmab A/S Sponsored ADR compare	n/m
BNTX BioNTech SE Sponsored ADR compare	n/m
RVMD Revolution Medicines, Inc. compare	n/m
INSM Insmed, Inc. compare	n/m
RPRX Royalty Pharma PLC compare	23.3×
ONC BeOne Medicines Ltd. - Sponsored ADR	30.4×
INCY Incyte Corporation compare	35.3×
ARGX argenex SE compare	41.0×
Biotechnology industry median	24.8×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

BeOne Medicines Ltd. - Sponsored ADR (ONC) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on ONC

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on ONC

Stockrow Weekly